Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Study to Assess the Safety, Tolerability and Pharmacokinetic Parameters of CN128 Tablets to Administration in Thalassemia Patients Aged 16 and Above

NCT03935633 is registered in ClinicalTrials.gov with Hangzhou Zede Pharma-Tech Co., Ltd. as lead sponsor.

NCT NCT03935633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03935633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Study to Assess the Safety, Tolerability and Pharmacokinetic Parameters of CN128 Tablets to Administration in Thalassemia Patients Aged 16 and Above
Lead sponsor
Hangzhou Zede Pharma-Tech Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 3, 2018
Completion date
December 17, 2019
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thalassemia